
Zachary J. Miknis
Examiner (ID: 14028, Phone: (571)272-7008 , Office: P/1675 )
| Most Active Art Unit | 1658 |
| Art Unit(s) | 1675, 1658, 1654 |
| Total Applications | 774 |
| Issued Applications | 479 |
| Pending Applications | 88 |
| Abandoned Applications | 227 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18339390
[patent_doc_number] => 20230131339
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-27
[patent_title] => EPI-X4 BASED PEPTIDES AND DERIVATIVES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/801684
[patent_app_country] => US
[patent_app_date] => 2021-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23690
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17801684
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/801684 | EPI-X4 BASED PEPTIDES AND DERIVATIVES THEREOF | Feb 25, 2021 | Pending |
Array
(
[id] => 18374437
[patent_doc_number] => 20230149516
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-18
[patent_title] => USE OF PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR THERAPEUTIC PURPOSE
[patent_app_type] => utility
[patent_app_number] => 17/802338
[patent_app_country] => US
[patent_app_date] => 2021-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22103
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 8
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17802338
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/802338 | USE OF PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR THERAPEUTIC PURPOSE | Feb 25, 2021 | Abandoned |
Array
(
[id] => 18497390
[patent_doc_number] => 20230220019
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-13
[patent_title] => CHEMICALLY-STABILIZED ALLOSTERIC MODULATORS OF LEUCINERICH REPEAT KINASE 2 (LRRK2)
[patent_app_type] => utility
[patent_app_number] => 17/802388
[patent_app_country] => US
[patent_app_date] => 2021-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23497
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17802388
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/802388 | Chemically-stabilized allosteric modulators of leucine-rich repeat kinase 2 (LRRK2) | Feb 24, 2021 | Issued |
Array
(
[id] => 17154917
[patent_doc_number] => 20210315968
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-14
[patent_title] => Prevention and Treatment of Viral Infection and Viral Infection-Induced Organ Failure
[patent_app_type] => utility
[patent_app_number] => 17/184781
[patent_app_country] => US
[patent_app_date] => 2021-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12022
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17184781
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/184781 | Prevention and treatment of viral infection and viral infection-induced organ failure | Feb 24, 2021 | Issued |
Array
(
[id] => 17168889
[patent_doc_number] => 20210322559
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-21
[patent_title] => Dimeric Collagen Hybridizing Peptides And Methods Of Using
[patent_app_type] => utility
[patent_app_number] => 17/184289
[patent_app_country] => US
[patent_app_date] => 2021-02-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15108
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17184289
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/184289 | Dimeric collagen hybridizing peptides and methods of using | Feb 23, 2021 | Issued |
Array
(
[id] => 16901153
[patent_doc_number] => 20210180069
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-17
[patent_title] => STRUCTURE, MANUFACTURING AND USES OF HUMAN-DERIVED CELL-PERMEABLE PEPTIDES CONJUGATED WITH SPECIFIC BIOLOGICALLY ACTIVE CARGO PEPTIDES
[patent_app_type] => utility
[patent_app_number] => 17/179079
[patent_app_country] => US
[patent_app_date] => 2021-02-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39073
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17179079
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/179079 | STRUCTURE, MANUFACTURING AND USES OF HUMAN-DERIVED CELL-PERMEABLE PEPTIDES CONJUGATED WITH SPECIFIC BIOLOGICALLY ACTIVE CARGO PEPTIDES | Feb 17, 2021 | Abandoned |
Array
(
[id] => 19732026
[patent_doc_number] => 12210018
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-28
[patent_title] => Compositions and methods related to the methylation of histone H1.0 protein
[patent_app_type] => utility
[patent_app_number] => 17/175540
[patent_app_country] => US
[patent_app_date] => 2021-02-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 33
[patent_figures_cnt] => 37
[patent_no_of_words] => 19792
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17175540
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/175540 | Compositions and methods related to the methylation of histone H1.0 protein | Feb 11, 2021 | Issued |
Array
(
[id] => 18604689
[patent_doc_number] => 11746139
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-09-05
[patent_title] => IL-7Ragc binding compounds
[patent_app_type] => utility
[patent_app_number] => 17/166462
[patent_app_country] => US
[patent_app_date] => 2021-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 39
[patent_no_of_words] => 63040
[patent_no_of_claims] => 37
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17166462
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/166462 | IL-7Ragc binding compounds | Feb 2, 2021 | Issued |
Array
(
[id] => 20171832
[patent_doc_number] => 12390552
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-19
[patent_title] => Self-assembling peptide gel formulation and methods of use
[patent_app_type] => utility
[patent_app_number] => 17/148180
[patent_app_country] => US
[patent_app_date] => 2021-01-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9735
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 184
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17148180
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/148180 | Self-assembling peptide gel formulation and methods of use | Jan 12, 2021 | Issued |
Array
(
[id] => 17007073
[patent_doc_number] => 20210238234
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-05
[patent_title] => ELICITOR PEPTIDES HAVING DISRUPTED HYPERSENSITIVE RESPONSE BOX AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/147183
[patent_app_country] => US
[patent_app_date] => 2021-01-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28337
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 149
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17147183
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/147183 | Elicitor peptides having disrupted hypersensitive response box and use thereof | Jan 11, 2021 | Issued |
Array
(
[id] => 20896475
[patent_doc_number] => 12703731
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-08-11
[patent_title] => Long-acting GLP-1 compound
[patent_app_type] => utility
[patent_app_number] => 17/758113
[patent_app_country] => US
[patent_app_date] => 2020-12-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 34
[patent_no_of_words] => 16853
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17758113
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/758113 | Long-Acting GLP-1 Compound | Dec 28, 2020 | Pending |
Array
(
[id] => 19490565
[patent_doc_number] => 12109250
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-08
[patent_title] => Methods and compositions for treatment of bone, skin, subcutaneous, mucosal and/or submucosal cancer by percutaneous and/or transmucosal administration of interferon
[patent_app_type] => utility
[patent_app_number] => 17/136656
[patent_app_country] => US
[patent_app_date] => 2020-12-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18820
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17136656
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/136656 | Methods and compositions for treatment of bone, skin, subcutaneous, mucosal and/or submucosal cancer by percutaneous and/or transmucosal administration of interferon | Dec 28, 2020 | Issued |
Array
(
[id] => 19067173
[patent_doc_number] => 20240101599
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-28
[patent_title] => PEPTIDE, CELL GROWTH PROMOTER, PROTEIN PRODUCTION PROMOTER, CULTURE MEDIUM, CELL GROWTH METHOD USING PEPTIDE, AND PROTEIN PRODUCTION METHOD USING PEPTIDE
[patent_app_type] => utility
[patent_app_number] => 18/267509
[patent_app_country] => US
[patent_app_date] => 2020-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9739
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18267509
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/267509 | PEPTIDE, CELL GROWTH PROMOTER, PROTEIN PRODUCTION PROMOTER, CULTURE MEDIUM, CELL GROWTH METHOD USING PEPTIDE, AND PROTEIN PRODUCTION METHOD USING PEPTIDE | Dec 21, 2020 | Pending |
Array
(
[id] => 17975528
[patent_doc_number] => 11492376
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-08
[patent_title] => None
[patent_app_type] => utility
[patent_app_number] => 17/130475
[patent_app_country] => US
[patent_app_date] => 2020-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 28
[patent_no_of_words] => 7684
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17130475
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/130475 | None | Dec 21, 2020 | Issued |
Array
(
[id] => 16837978
[patent_doc_number] => 20210145990
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-20
[patent_title] => MINI-GASTRIN ANALOGUE, IN PARTICULAR FOR USE IN CCK2 RECEPTOR POSITIVE TUMOUR DIAGNOSIS AND/OR TREATMENT
[patent_app_type] => utility
[patent_app_number] => 17/127265
[patent_app_country] => US
[patent_app_date] => 2020-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2214
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17127265
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/127265 | Mini-gastrin analogue, in particular for use in CCK2 receptor positive tumour diagnosis and/or treatment | Dec 17, 2020 | Issued |
Array
(
[id] => 18109568
[patent_doc_number] => 20230002448
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-05
[patent_title] => COLLAGEN PRODUCTION
[patent_app_type] => utility
[patent_app_number] => 17/782948
[patent_app_country] => US
[patent_app_date] => 2020-12-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13803
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17782948
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/782948 | COLLAGEN PRODUCTION | Dec 10, 2020 | Pending |
Array
(
[id] => 17997857
[patent_doc_number] => 11498951
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-15
[patent_title] => Insulin analogues and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/117263
[patent_app_country] => US
[patent_app_date] => 2020-12-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 16557
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17117263
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/117263 | Insulin analogues and uses thereof | Dec 9, 2020 | Issued |
Array
(
[id] => 18418626
[patent_doc_number] => 20230173084
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => PEPTIDE-BASED SYNTHETIC CHLORIDE ION TRANSPORTERS
[patent_app_type] => utility
[patent_app_number] => 17/782603
[patent_app_country] => US
[patent_app_date] => 2020-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8458
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17782603
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/782603 | PEPTIDE-BASED SYNTHETIC CHLORIDE ION TRANSPORTERS | Dec 6, 2020 | Abandoned |
Array
(
[id] => 18239060
[patent_doc_number] => 20230071371
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-09
[patent_title] => PEPTIDE CONJUGATES AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/782573
[patent_app_country] => US
[patent_app_date] => 2020-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50851
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -168
[patent_words_short_claim] => 10
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17782573
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/782573 | Peptide conjugates and methods of use | Dec 2, 2020 | Issued |
Array
(
[id] => 18144473
[patent_doc_number] => 20230018324
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-19
[patent_title] => METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF TYPE 1 DIABETES
[patent_app_type] => utility
[patent_app_number] => 17/778624
[patent_app_country] => US
[patent_app_date] => 2020-11-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7915
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -64
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17778624
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/778624 | Methods and compositions for the treatment and prevention of type 1 diabetes | Nov 24, 2020 | Issued |